Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Targeted therapies have opened new perspectives in clinical oncology. However, clinicians have observed a lack of response in a relevant percentage of patients and frequent relapse in patients who initially respond. Therefore, a compelling challenge is to identify mechanisms underlying resistance and strategies to circumvent these hurdles. A growing body of evidence indicates that MET, the tyrosine kinase receptor for hepatocyte growth factor (HGF), is frequently implicated in resistance to targeted therapies. In this review, we highlight cell-autonomous and non–cell-autonomous mechanisms through which MET drives resistance, and we discuss some unsolved issues related to the selection of patients who could benefit from combined therapies. Significance: Resistance is, at present, the major limitation to the efficacy of targeted therapies. Inappropriate MET activation is very frequently implicated in the onset of primary and secondary resistance to these therapies. Deciphering the role of the HGF/MET axis in resistance to different drugs could guide the design of new clinical trials based on combinatorial therapies, and it might help to overcome, or possibly prevent, the onset of resistance. Cancer Discov; 3(9); 978–92. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
(2012) · doi:10.1016/j.jmoldx.2011.08.002 · Cited by 2,567 · cited 1×
“This issue could be overcome by the use of recently developed in situ hybridization techniques (75).”
BackgroundYu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · cited 1×
“It has to be noted that more recent studies in rebiopsed specimens from larger cohorts revealed a lower frequency of MET amplification in resistant tumors compared with that reported by Engelman and Bean, ranging from 5 to 11% (32, 33).”
ResultDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“The presence of KRAS mutations and deregulation of effectors of the EGFR signaling cascade (PIK3CA, PTEN, NRAS) or of EGFR modulators (HER2, EGFR ligands) are thought to impair primary response to EGFR blockade (43-45).”
BackgroundEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 2×
“Moreover, all responding patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases (46, 47) .”
BackgroundMethodTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 2×
“(58), who showed that HGF treatment could rapidly promote resistance to lapatinib (a HER2 inhibitor) in HER2-amplified breast cancer cells, likely by driving selection of a subpopulation of MET-amplified cells.”
BackgroundThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 2×
“Moreover, all responding patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases (46, 47) .”
BackgroundBerns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627 · cited 1×
“trastuzumab treatment (38-40), a role for MET has been reported by Shattuck and colleagues (41), who found that inhibition of MET sensitizes cells to trastuzumabmediated growth inhibition, whereas MET activation protects cells against trastuzumab.”
BackgroundBean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · cited 1×
“The work published by Bean and colleagues (31) confirmed these results.”
ResultBussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., & Comoglio, P. M. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.629 · Cited by 1,337 · cited 1×
“HGF is an angiogenic factor (59) that is able to activate MET in endothelial cells, in part by inducing VEGF production and decreasing thrombospondin-1 expression (60).”
BackgroundThe discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 1×
“Targeted therapies by means of compounds that inhibit a specific target molecule give a new perspective in the treatment of cancer (1).”
BackgroundWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 2×
“Several studies have suggested that factors such as FGF2 or platelet derived growth factor, produced by either cancer or stromal cells, can contribute to the onset of resistance (57, 61).”
BackgroundPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · cited 2×
“breaks in fragile sites, such as the one in which the MET gene is located (34)? To answer these questions, Turke and colleagues (35) analyzed the HCC827 NSCLC cell line that, upon gefitinib treatment, became resistant via MET amplification.”
BackgroundBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892 · cited 1×
“However, it soon became clear that other cells of the microenvironment, such as cancer-associated fibroblasts and inflammatory cells, can also modulate the biological properties of tumor cells, impacting on their growth and invasion potential (55).”
BackgroundActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Self-citationMet receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473 · cited 1×
“trastuzumab treatment (38-40), a role for MET has been reported by Shattuck and colleagues (41), who found that inhibition of MET sensitizes cells to trastuzumabmediated growth inhibition, whereas MET activation protects cells against trastuzumab.”
BackgroundCross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells*
Jo, M., Stolz, D. B., Esplen, J. E., Dorko, K., Michalopoulos, G. K., & Strom, S. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8806 · Cited by 347
Wang, X., DeFrances, M. C., Dai, Y., Pediaditakis, P., Johnson, C., Bell, A., Michalopoulos, G. K., & Zarnegar, R. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00439-2 · Cited by 225 · cited 1×
“In addition, the interaction between MET and FAS, is important in the modulation of apoptosis (11).”
BackgroundHGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0568 · Cited by 176 · cited 1×
“(72) showed that in colorectal cancer cells, HGF-induced MET activation could release cells from cetuximabmediated EGFR inhibition, suggesting that inhibition of the MET/HGF pathway may also improve the response to EGFR inhibitors in colorectal cancer.”
BackgroundMinuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127
Cited by
New horizons in tumor microenvironment biology: challenges and opportunities
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0278-7 · Cited by 704
“Recent studies intensively evaluated the functional roles of TME in protecting acute myeloid leukemia cells or chronic lymphocytic leukemia cells against alkylating agents, anthracyclines, imatinib and nucleoside analogues, mutant Janus kinase 2 (JAK2) cells against JAK inhibitors including tofacitinib and ruxolitinib…”
BackgroundImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Li, Z., Yanfang, W., Li, J., Jiang, P., Peng, T., Chen, K., Zhao, X., Zhang, Y., Zhen, P., Zhu, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.035 · Cited by 338
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Metadata
- Authors
- Corso, S., & Giordano, S.
- Venue
- Cancer Discovery
- Published
- 2013-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 978-992
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2142857044
- Cited by
- 92
- References
- 23
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.